Karuna to advance lead drug into Phase 3 for psychosis in schizophrenia patients [Seeking Alpha]
Karuna Therapeutics, Inc. (KRTX)
Company Research
Source: Seeking Alpha
HealthcareKaruna to advance lead drug into Phase 3 for psychosis in schizophrenia patientsJun. 23, 2020 6:56 AM ET|Karuna Therapeutics, Inc. (KRTX)Douglas W. HouseFresh off a meeting with the FDA, Karuna Therapeutics (NASDAQ:developmentThe agency is on board with one successful late-stage study, along with additional safety data and results from previously generated trials, to support an NDA filing.It plans to launch two five-week trials, the first to launch by year-end. The primary endpoint of the 250-subject first study will be the change in Positive and Negative Syndrome Scale total score at week 5 versus placebo.Details of the second efficacy trial will be finalized in Q4 and should launch in H1 2021.It will also collect long-term open-label safety and tolerability data for up to one year in an outpatient setting.KarXT is an orally available combination of xanomeline (a novel muscarinic receptor agonist) and trospium (a muscarinic receptor antagonist). The company says it has the
Show less
Read more
Impact Snapshot
Event Time:
KRTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
KRTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
KRTX alerts
High impacting Karuna Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
KRTX
News
- PureTech Proposes $100 Million Capital Return [Yahoo! Finance]Yahoo! Finance
- Bristol Myers Squibb Completes Acquisition of PureTech's Founded Entity Karuna Therapeutics for $14 Billion [Yahoo! Finance]Yahoo! Finance
- Loss-Making Karuna Therapeutics, Inc. (NASDAQ:KRTX) Expected To Breakeven In The Medium-Term [Yahoo! Finance]Yahoo! Finance
- Sofinnova Investments Appoints Troy Ignelzi as Executive Advisor [Yahoo! Finance]Yahoo! Finance
- Bronte Amalthea Fund Incurred Loss in Karuna Therapeutics (KRTX) Short Position [Yahoo! Finance]Yahoo! Finance
KRTX
Earnings
- 2/22/24 - Miss
KRTX
Sec Filings
- 3/18/24 - Form 4
- 3/18/24 - Form 4
- 3/18/24 - Form 4
- KRTX's page on the SEC website